Seraphina Therapeutics Inc.

Seraphina Therapeutics Inc. pioneers the creation of evidence-driven consumer health products, focusing on fatty acids to enhance nutrient replenishment essential for health, particularly in aging populations. Founded in 2017 and headquartered in San Diego, US, Seraphina Therapeutics Inc. specializes in nutritional health products.

The company was co-founded by Eric Venn-Watson and Stephanie Venn-Watson, the latter also serves as the CEO. In October 2021, the company raised USD 5 mn in Series A funding, with participation from investors including Cue Ball Capital and Domain Associates. Seraphina Therapeutics specializes in developing consumer health products centered around key fatty acids. Its flagship product, C15:0 (pentadecanoic acid), is derived from natural sources such as butter and certain fish, aimed at improving health outcomes by replenishing essential micronutrients.

The company targets health-conscious individuals and the aging population, marketing its products across North America and Europe, where demand for health supplements is increasing. Seraphina Therapeutics generates revenue through direct-to-consumer sales and partnerships with health and wellness retailers, primarily through its flagship product, C15:0. The pricing strategy reflects the premium nature of the product, targeting both individual consumers and larger distribution channels to maximize market reach and customer engagement. Following its Series A funding round in October 2021, Seraphina Therapeutics Inc.

will utilize the USD 5 mn raised to expand its subscription platform and enhance ingredient opportunities for C15:0. The company aims to broaden its product offerings and develop new health solutions, while also exploring expansion into additional geographical markets to meet rising consumer demand.